Physician profile
Cara E Smith
NPI 1417262387
$5,009.33
in general payments reported to CMS, 2019-2025
37 companies · $28.26 in 2025
The $28.26 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $379 · 2020: $302 · 2021: $185 · 2022: $297 · 2023: $296 · 2024: $3,522 · 2025: $28.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,515 · Education: $1,500 · Food and Beverage: $832.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,514.59 |
| Education | $1,500.00 |
| Food and Beverage | $832.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,164.36 | 2024 | |
| Abbvie INC. | $272.09 | 2019-2025 | Orilissa, Lo Loestrin Fe |
| Hologic Sales and Service, LLC | $189.08 | 2019-2024 | Aptima, Thinprep 2000 Processor, Coolseal Generator |
| Organon LLC | $128.21 | 2023-2024 | Nexplanon |
| Pfizer INC. | $116.22 | 2019-2023 | |
| Glaxosmithkline, LLC. | $97.48 | 2019 | |
| Medtronic, INC. | $95.73 | 2021-2022 | |
| Aspira Women'S Health INC | $79.82 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $75.52 | 2021-2024 | |
| Sumitomo Pharma America, INC. | $75.35 | 2024 | Gemtesa, Myfembree |
| Coopersurgical, INC. | $68.00 | 2019-2024 | Paragard T 380a |
| Exeltis, USA INC. | $59.66 | 2019-2024 | Slynd |
| Dysis Medical, INC. | $55.04 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.62 | 2021-2023 | |
| Lupin INC. | $36.38 | 2020 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Pharmaceuticals INC. | $32.45 | 2019-2021 | |
| Mission Pharmacal Company | $31.26 | 2020-2021 | |
| Astellas Pharma US INC | $29.72 | 2023-2024 | Veozah |
| Amag Pharmaceuticals, INC. | $29.58 | 2019 | |
| Biogen, INC. | $29.34 | 2024 | Zurzuvae |
| Ethicon US, LLC | $28.56 | 2020 | |
| Amgen INC. | $27.89 | 2019-2020 | |
| Therapeuticsmd, INC. | $26.12 | 2019 | |
| Millicent US INC | $22.11 | 2024 | Intrarosa, Femring |
| Gynesonics, INC. | $20.44 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Shield Therapeutics INC | $18.83 | 2022 | |
| Sage Therapeutics, LLC | $18.44 | 2022 | |
| Axonics, INC. | $17.79 | 2023 | Axonics |
| Merck Sharp & Dohme LLC | $17.13 | 2020 | |
| Avion Pharmaceuticals | $15.74 | 2020 | |
| Ascend Therapeutics US, LLC | $15.73 | 2021 | |
| Biotissue Holdings INC. | $15.73 | 2024 | |
| Meditrina | $12.10 | 2023 | |
| Agile Therapeutics, INC. | $12.09 | 2021 | |
| Duchesnay USA Incorporated | $11.82 | 2019 | |
| Zyla Life Sciences, INC. | $11.01 | 2020 | |
| Allergan, INC. | $10.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cara Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.